Cargando…

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Kucharz, Eugeniusz J., Stajszczyk, Marcin, Kotulska-Kucharz, Anna, Batko, Bogdan, Brzosko, Marek, Jeka, Sławomir, Leszczyński, Piotr, Majdan, Maria, Olesińska, Marzena, Samborski, Włodzimierz, Wiland, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142023/
https://www.ncbi.nlm.nih.gov/pubmed/30237624
http://dx.doi.org/10.5114/reum.2018.77971
_version_ 1783355794914279424
author Kucharz, Eugeniusz J.
Stajszczyk, Marcin
Kotulska-Kucharz, Anna
Batko, Bogdan
Brzosko, Marek
Jeka, Sławomir
Leszczyński, Piotr
Majdan, Maria
Olesińska, Marzena
Samborski, Włodzimierz
Wiland, Piotr
author_facet Kucharz, Eugeniusz J.
Stajszczyk, Marcin
Kotulska-Kucharz, Anna
Batko, Bogdan
Brzosko, Marek
Jeka, Sławomir
Leszczyński, Piotr
Majdan, Maria
Olesińska, Marzena
Samborski, Włodzimierz
Wiland, Piotr
author_sort Kucharz, Eugeniusz J.
collection PubMed
description Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular nucleus and inhibits the inflammation process via a new pathway (inhibition of the Janus kinases), which is unavailable to biological medicines. Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic disease-modifying antirheumatic drug or in monotherapy. The efficacy of tofacitinib has been confirmed in several clinical trials. The drug inhibits radiographic progression of the disease. The innovative mechanism of action of tofacitinib is a noteworthy feature because it offers hope of effective treatment for patients who fail to respond to other drugs. The presented article discusses the mechanism of action and the clinical application of tofacitinib. Tofacitinib represents a new group of disease-modifying antirheumatic drugs that can be placed on an equal footing with biological drugs already available.
format Online
Article
Text
id pubmed-6142023
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
record_format MEDLINE/PubMed
spelling pubmed-61420232018-09-20 Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology Kucharz, Eugeniusz J. Stajszczyk, Marcin Kotulska-Kucharz, Anna Batko, Bogdan Brzosko, Marek Jeka, Sławomir Leszczyński, Piotr Majdan, Maria Olesińska, Marzena Samborski, Włodzimierz Wiland, Piotr Reumatologia Recommendations for Diagnosis and Treatment Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular nucleus and inhibits the inflammation process via a new pathway (inhibition of the Janus kinases), which is unavailable to biological medicines. Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic disease-modifying antirheumatic drug or in monotherapy. The efficacy of tofacitinib has been confirmed in several clinical trials. The drug inhibits radiographic progression of the disease. The innovative mechanism of action of tofacitinib is a noteworthy feature because it offers hope of effective treatment for patients who fail to respond to other drugs. The presented article discusses the mechanism of action and the clinical application of tofacitinib. Tofacitinib represents a new group of disease-modifying antirheumatic drugs that can be placed on an equal footing with biological drugs already available. Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018-08-31 2018 /pmc/articles/PMC6142023/ /pubmed/30237624 http://dx.doi.org/10.5114/reum.2018.77971 Text en Copyright: © 2018 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Recommendations for Diagnosis and Treatment
Kucharz, Eugeniusz J.
Stajszczyk, Marcin
Kotulska-Kucharz, Anna
Batko, Bogdan
Brzosko, Marek
Jeka, Sławomir
Leszczyński, Piotr
Majdan, Maria
Olesińska, Marzena
Samborski, Włodzimierz
Wiland, Piotr
Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title_full Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title_fullStr Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title_full_unstemmed Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title_short Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
title_sort tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the polish society for rheumatology
topic Recommendations for Diagnosis and Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142023/
https://www.ncbi.nlm.nih.gov/pubmed/30237624
http://dx.doi.org/10.5114/reum.2018.77971
work_keys_str_mv AT kucharzeugeniuszj tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT stajszczykmarcin tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT kotulskakucharzanna tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT batkobogdan tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT brzoskomarek tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT jekasławomir tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT leszczynskipiotr tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT majdanmaria tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT olesinskamarzena tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT samborskiwłodzimierz tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology
AT wilandpiotr tofacitinibinthetreatmentofpatientswithrheumatoidarthritispositionstatementofexpertsofthepolishsocietyforrheumatology